Neurovascular Intervention

Sphenopalatine ganglion stimulation is safe for patients with acute ischaemic stroke 8–24 h after onset, who are ineligible for thrombolytic therapy. Although not reaching significance, the trial's results support that, among patients with imaging evidence of cortical involvement at presentation, sphenopalatine ganglion stimulation is likely to improve functional outcome.

The ANA™ thrombectomy system is a novel stroke thrombectomy device comprising a self-expanding funnel designed to reduce clot fragmentation by locally restricting flow while becoming as wide as the lodging artery.

Donald Ricci, president and Chief Executive Officer of Evac commented, “We have listened to the experts in the neuro field and developed an improved version that is smaller and easier to use. This will allow treatment for a wider range of aneurysms and shorten delivery times,” he continued, “The previous version showed exceptional outcome due to the eCLIPs implant’s ability to bridge the neck of the aneurysm and to create a flow diversion effect. This new and improved version retains these favourable characteristics and also allows eCLIPs to gain access to smaller and more distant vessels within the cerebral anatomy.”

During this course EMS providers will be introduced to LVO stroke, as well as a sample of stroke severity scales that are intended to accurately predict LVO stroke in the field. This course will also present how EMS providers can improve prehospital stroke screening, documentation, and communication with receiving stroke centers.

HPC is an aneurysm implant and Flow Diverter coating, which shall reduce the risk of thrombosis on the surface of stents. Due to the thrombogenic surface, platelet function-inhibiting drugs are needed to prevent in-stent thrombosis. The current solution of preventing platelet activation is the Dual Anti-Platelet Therapy (DAPT) consisting of Aspirin and Clopidogrel.

Aviceanna.AI has announced that its medical imaging artificial intelligence (AI) tool, CINA Head, has qualified for the new technology add-on payment (NTAP) recently approved by the Centers for Medicare and Medicaid Services (CMS).

A new case study reveals a link between COVID-19 and clotting in blood vessels in the brain that results in an increased risk of ischemic stroke. Five of the six cases included in the study suffered an ischemic stroke within 8-24 days of the onset of coronavirus symptoms. Early use of anticoagulants might help reduce the risk of blood clotting and stroke in patients with COVID-19.

After diabetes, Medtronic is looking to leverage AI through a distribution agreement with Viz.ai, which uses the technology to streamline stroke care.

All in One Suit for Stroke Rehabilitation covering upper body, lower body, hand eye coordination and body posture

Synchron has been awarded nearly AUD$1M ($990,000) in funding from the Medical Research Future Fund (MRFF), through MTPConnect, the Australian Government’s BioMedTech Horizons (BMTH) programme, to advance the commercialisation of Synchron’s Stentrode. Stentrode is a minimally-invasive brain-computer interface being designed to restore functional independence, including the ability to text message, for people with paralysis by facilitating control of external personal devices through thought alone, and without the need for open brain surgery.

Cerus Endovascular has announced that it has received CE mark approval for its CerusEndo MC 021 microcatheter, designed to allow physicians to access tortuous neurovasculature and deliver therapeutic devices to intended targets.

A novel tandem stent thrombectomy technique “seems to be a safe and effective” rescue treatment for acute large vessel occlusion (LVO) that is resistant to conventional attempts, concludes a study recently published in the Journal of NeuroInterventional Surgery.

From acute interventions to endovascular therapy indication expansion, Sunil Sheth from McGovern Medical School at UTHealth, Houston, USA, kick-started the Society of NeuroInterventional Surgery’s (SNIS) annual meeting (4–7 August) by outlining an array of recently completed, and ongoing stroke trials.

Non-internal carotid artery (non-ICA) site of occlusion, the use of a balloon-guided catheter, and better collateral grade were all independent predictors of the first-pass effect, concluded Ashutosh Jadhav from the University of Pittsburgh, Pittsburgh, USA, at the recent Society of NeuroInterventional Surgery’s (SNIS) annual meeting (22–25 July, Miami, USA).

The paper: “Mechanical thrombectomy with a novel stent retriever with multifunctional zones: Initial clinical experience with the NeVa thrombectomy device,” was recently published in the Journal of Neuroradiology. The data demonstrated that NeVa achieved a high rate of first pass success and overall reperfusion scores with no device related complications.

In patients with suspected acute stroke, MethinksLVO software can rapidly and reliably predict LVO. MethinksLVO could reduce the need to perform CTA, generate alarms, and increase the efficiency of patient transfers in stroke networks.